Reactivation of Hepatitis B Virus During Treatment of Hepatitis C Genotype 3 with Daclatasvir and Sofosbuvir in a Patient with Dual Infection of Hepatitis B and Hepatitis C Virus
Introduction: The recent use of new direct-acting drugs (DAAs) in the treatment of chronic hepatitis C needs to be evaluated in HBV/HCV coinfected patients. Case Presentation: Here, we report the case of a 47-year-old female patient with HBV/HCV coinfection who experienced HBV reactivation during tr...
Gespeichert in:
| Veröffentlicht in: | Hepatitis monthly 2018-01, Vol.18 (1) |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | |
| container_title | Hepatitis monthly |
| container_volume | 18 |
| creator | Zacharakis, Georgios Alzahrani, Jaman |
| description | Introduction: The recent use of new direct-acting drugs (DAAs) in the treatment of chronic hepatitis C needs to be evaluated in HBV/HCV coinfected patients. Case Presentation: Here, we report the case of a 47-year-old female patient with HBV/HCV coinfection who experienced HBV reactivation during treatment with daclatasvir (DCV) and sofosbuvir (SOF). In addition to the DAAs, Entecavir (ETV) was added to the combined regimen with improvement in ALT levels. Conclusions: Both HBV and HCV treatment could be implemented effectively in case of reactivation of HBV during anti-HCV treatment with DAAs. Close monitoring of HBV DNA and ALT levels are highly recommended during DAAs drug therapy for HCV in patients with HBV/HCV dual infection. |
| doi_str_mv | 10.5812/hepatmon.12531 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2086270002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2086270002</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-ad75b044a0faea1a44b0617db48d4a28847a2fbc73f64ce01f8a2dc797562b5e3</originalsourceid><addsrcrecordid>eNptkU9Lw0AQxYMoWKtXzwueU_dfsvGoVdtCQdEq3sIk2bVb2t24u6n0a_kJTdoKCp5mBn7vzYMXRecED5KM0Mu5rCGsrBkQmjByEPWIYEnMOM4O9zvh7O04OvF-gXGSYUF70deThDLoNQRtDbIKjTsXHbRHN-hVu8aj28Zp845mTrb20oS_1BCNpLFhU0vE0KcOc3QL5RIC-LV2CEyFnq2yvmi6UxsE6LFVdjY7uIElmhgly_8CdPLfr7aBTqMjBUsvz_azH73c382G43j6MJoMr6dxybAIMVQiKTDngBVIIMB5gVMiqoJnFQeaZVwAVUUpmEp5KTFRGdCqFFciSWmRSNaPLna-tbMfjfQhX9jGmfZlTnGWUoExpi012FGls947qfLa6RW4TU5w3vWS__SSb3th34KShTs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2086270002</pqid></control><display><type>article</type><title>Reactivation of Hepatitis B Virus During Treatment of Hepatitis C Genotype 3 with Daclatasvir and Sofosbuvir in a Patient with Dual Infection of Hepatitis B and Hepatitis C Virus</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Zacharakis, Georgios ; Alzahrani, Jaman</creator><creatorcontrib>Zacharakis, Georgios ; Alzahrani, Jaman</creatorcontrib><description>Introduction: The recent use of new direct-acting drugs (DAAs) in the treatment of chronic hepatitis C needs to be evaluated in HBV/HCV coinfected patients. Case Presentation: Here, we report the case of a 47-year-old female patient with HBV/HCV coinfection who experienced HBV reactivation during treatment with daclatasvir (DCV) and sofosbuvir (SOF). In addition to the DAAs, Entecavir (ETV) was added to the combined regimen with improvement in ALT levels. Conclusions: Both HBV and HCV treatment could be implemented effectively in case of reactivation of HBV during anti-HCV treatment with DAAs. Close monitoring of HBV DNA and ALT levels are highly recommended during DAAs drug therapy for HCV in patients with HBV/HCV dual infection.</description><identifier>ISSN: 1735-143X</identifier><identifier>EISSN: 1735-3408</identifier><identifier>DOI: 10.5812/hepatmon.12531</identifier><language>eng</language><publisher>Tehran: Tehran Hepatitis Center</publisher><subject>Antiviral drugs ; Clinical medicine ; Deoxyribonucleic acid ; DNA ; Genotype & phenotype ; Hepatitis ; Hepatitis B ; Hepatitis C ; Infections ; Interferon ; Liver diseases ; Patients ; Viruses</subject><ispartof>Hepatitis monthly, 2018-01, Vol.18 (1)</ispartof><rights>2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c307t-ad75b044a0faea1a44b0617db48d4a28847a2fbc73f64ce01f8a2dc797562b5e3</citedby><cites>FETCH-LOGICAL-c307t-ad75b044a0faea1a44b0617db48d4a28847a2fbc73f64ce01f8a2dc797562b5e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Zacharakis, Georgios</creatorcontrib><creatorcontrib>Alzahrani, Jaman</creatorcontrib><title>Reactivation of Hepatitis B Virus During Treatment of Hepatitis C Genotype 3 with Daclatasvir and Sofosbuvir in a Patient with Dual Infection of Hepatitis B and Hepatitis C Virus</title><title>Hepatitis monthly</title><description>Introduction: The recent use of new direct-acting drugs (DAAs) in the treatment of chronic hepatitis C needs to be evaluated in HBV/HCV coinfected patients. Case Presentation: Here, we report the case of a 47-year-old female patient with HBV/HCV coinfection who experienced HBV reactivation during treatment with daclatasvir (DCV) and sofosbuvir (SOF). In addition to the DAAs, Entecavir (ETV) was added to the combined regimen with improvement in ALT levels. Conclusions: Both HBV and HCV treatment could be implemented effectively in case of reactivation of HBV during anti-HCV treatment with DAAs. Close monitoring of HBV DNA and ALT levels are highly recommended during DAAs drug therapy for HCV in patients with HBV/HCV dual infection.</description><subject>Antiviral drugs</subject><subject>Clinical medicine</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Genotype & phenotype</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>Infections</subject><subject>Interferon</subject><subject>Liver diseases</subject><subject>Patients</subject><subject>Viruses</subject><issn>1735-143X</issn><issn>1735-3408</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkU9Lw0AQxYMoWKtXzwueU_dfsvGoVdtCQdEq3sIk2bVb2t24u6n0a_kJTdoKCp5mBn7vzYMXRecED5KM0Mu5rCGsrBkQmjByEPWIYEnMOM4O9zvh7O04OvF-gXGSYUF70deThDLoNQRtDbIKjTsXHbRHN-hVu8aj28Zp845mTrb20oS_1BCNpLFhU0vE0KcOc3QL5RIC-LV2CEyFnq2yvmi6UxsE6LFVdjY7uIElmhgly_8CdPLfr7aBTqMjBUsvz_azH73c382G43j6MJoMr6dxybAIMVQiKTDngBVIIMB5gVMiqoJnFQeaZVwAVUUpmEp5KTFRGdCqFFciSWmRSNaPLna-tbMfjfQhX9jGmfZlTnGWUoExpi012FGls947qfLa6RW4TU5w3vWS__SSb3th34KShTs</recordid><startdate>20180120</startdate><enddate>20180120</enddate><creator>Zacharakis, Georgios</creator><creator>Alzahrani, Jaman</creator><general>Tehran Hepatitis Center</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20180120</creationdate><title>Reactivation of Hepatitis B Virus During Treatment of Hepatitis C Genotype 3 with Daclatasvir and Sofosbuvir in a Patient with Dual Infection of Hepatitis B and Hepatitis C Virus</title><author>Zacharakis, Georgios ; Alzahrani, Jaman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-ad75b044a0faea1a44b0617db48d4a28847a2fbc73f64ce01f8a2dc797562b5e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antiviral drugs</topic><topic>Clinical medicine</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Genotype & phenotype</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>Infections</topic><topic>Interferon</topic><topic>Liver diseases</topic><topic>Patients</topic><topic>Viruses</topic><toplevel>online_resources</toplevel><creatorcontrib>Zacharakis, Georgios</creatorcontrib><creatorcontrib>Alzahrani, Jaman</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Hepatitis monthly</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zacharakis, Georgios</au><au>Alzahrani, Jaman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reactivation of Hepatitis B Virus During Treatment of Hepatitis C Genotype 3 with Daclatasvir and Sofosbuvir in a Patient with Dual Infection of Hepatitis B and Hepatitis C Virus</atitle><jtitle>Hepatitis monthly</jtitle><date>2018-01-20</date><risdate>2018</risdate><volume>18</volume><issue>1</issue><issn>1735-143X</issn><eissn>1735-3408</eissn><abstract>Introduction: The recent use of new direct-acting drugs (DAAs) in the treatment of chronic hepatitis C needs to be evaluated in HBV/HCV coinfected patients. Case Presentation: Here, we report the case of a 47-year-old female patient with HBV/HCV coinfection who experienced HBV reactivation during treatment with daclatasvir (DCV) and sofosbuvir (SOF). In addition to the DAAs, Entecavir (ETV) was added to the combined regimen with improvement in ALT levels. Conclusions: Both HBV and HCV treatment could be implemented effectively in case of reactivation of HBV during anti-HCV treatment with DAAs. Close monitoring of HBV DNA and ALT levels are highly recommended during DAAs drug therapy for HCV in patients with HBV/HCV dual infection.</abstract><cop>Tehran</cop><pub>Tehran Hepatitis Center</pub><doi>10.5812/hepatmon.12531</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1735-143X |
| ispartof | Hepatitis monthly, 2018-01, Vol.18 (1) |
| issn | 1735-143X 1735-3408 |
| language | eng |
| recordid | cdi_proquest_journals_2086270002 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Antiviral drugs Clinical medicine Deoxyribonucleic acid DNA Genotype & phenotype Hepatitis Hepatitis B Hepatitis C Infections Interferon Liver diseases Patients Viruses |
| title | Reactivation of Hepatitis B Virus During Treatment of Hepatitis C Genotype 3 with Daclatasvir and Sofosbuvir in a Patient with Dual Infection of Hepatitis B and Hepatitis C Virus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T12%3A16%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reactivation%20of%20Hepatitis%20B%20Virus%20During%20Treatment%20of%20Hepatitis%20C%20Genotype%203%20with%20Daclatasvir%20and%20Sofosbuvir%20in%20a%20Patient%20with%20Dual%20Infection%20of%20Hepatitis%20B%20and%20Hepatitis%20C%20Virus&rft.jtitle=Hepatitis%20monthly&rft.au=Zacharakis,%20Georgios&rft.date=2018-01-20&rft.volume=18&rft.issue=1&rft.issn=1735-143X&rft.eissn=1735-3408&rft_id=info:doi/10.5812/hepatmon.12531&rft_dat=%3Cproquest_cross%3E2086270002%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2086270002&rft_id=info:pmid/&rfr_iscdi=true |